CLAIMS

What is claimed is:

5

10

15

1. A method of treating multiple sclerosis, the method comprising administering to a patient having multiple sclerosis a therapeutically effective amount of a compound of Formula I

wherein M is a natural (L) alpha amino acid derivative having the structure

X is $O(S, S(O)_n)$, CH_2 , CO, or NRQ;

RQ is hydrogen, C₁-C₆ alkyl, or -C₁-C₆ alkyl-phenyl;

R is a side chain of a natural alpha amino acid;

R¹ is C₁-C₅ alkoxy, hydroxy, or -NHOR⁵;

 ${\rm R}^2$ and ${\rm R}^4$ are independently hydrogen, -C1-C5 alkyl, phenyl -NO2,

halogen, -OR 5 , -CN, -CO $_2$ R 5 , -SO $_3$ R 5 ,-CHO, -COR 5 ,

-CONR 5 R 6 , -(CH $_2$)_nNR 5 R 6 , -CF $_3$, or -NHCOR 5 ;

each R^5 and R^6 are independently hydrogen or C_1 - C_5 alkyl; and n is 0 to 2, and the pharmaceutically acceptable salts, esters, and amides thereof, wherein the esters thereof are selected from C_1 - C_6 alkyl esters, C_5 - C_7 cycloalkyl esters, and arylalkyl esters and the amides thereof are

derived from ammonia, primary C_1 - C_6 alkyl amines, secondary C_1 - C_6 dialkyl, and 5- and 6-membered heterocyclic amines containing one nitrogen atom; and wherein the group $S(=O)_2M$ is optionally bonded to the 1-, 2-, or 3-position of Formula I.

5

2. A method of treating arthritis, the method comprising administering to a patient having arthritis a therapeutically effective amount of a compound of Formula I

10

15

wherein M is a natural (L) alpha amino acid derivative having the structure

$$COR^{1}$$

$$-N - H$$

$$R$$
 $X \text{ is } O(S, S(O)_{n}, CH_{2}, CO, \text{ or } NRQ;$

RQ is hydrogen, C₁-C₆ alkyl, or -C₁-C₆ alkyl-phenyl;

R is a side chain of a natural alpha amino acid;

 R^1 is C_1 - C_5 alkoxy, hydroxy, or -NHOR 5 ;


 $\ensuremath{\mathsf{R}}^2$ and $\ensuremath{\mathsf{R}}^4$ are independently hydrogen, -C1-C5 alkyl, phenyl -NO2,

halogen, $-OR^5$, -CN, $-CO_2R^5$, $-SO_3R^5$, -CHO, $-COR^5$,

-CONR⁵R⁶, -(CH₂)_nNR⁵R⁶, -CF₃, or -NHCOR⁵;

each ${\rm R}^5$ and ${\rm R}^6$ are independently hydrogen or ${\rm C}_1\text{-}{\rm C}_5$ alkyl; and

n is 0 to 2, and the pharmaceutically acceptable salts, esters, and amides thereof, wherein the esters thereof are selected from C_1 - C_6 alkyl esters, C_5 - C_7 cycloalkyl esters, and arylalkyl esters and the amides thereof are derived from ammonia, primary C_1 - C_6 alkyl amines, secondary C_1 - C_6 dialkyl, and 5- and 6-membered heterocyclic amines containing one nitrogen atom; and wherein the group $S(=O)_2M$ is optionally bonded to the 1-, 2-, or 3-position of Formula I.



wherein M is a natural (L) alpha amino acid derivative having the structure

5

15

Rb is a side chain of a natural alpha amino acid;

R^a is C₁-C₅ alkoxy, hydroxy, or -NHOR⁵;

 $\ensuremath{\mathsf{R}}^2$ and $\ensuremath{\mathsf{R}}^4$ are independently hydrogen, -C1-C5 alkyl, phenyl -NO2,

halogen, $-OR^5$, -CN, $-CO_2R^5$, $-SO_3R^5$, -CHO, $-COR^5$,

-CONR⁵R⁶, -(CH₂)_nNR⁵R⁶, -CF₃, or -NHCOR⁵;

each ${\rm R}^5$ and ${\rm R}^6$ are independently hydrogen or ${\rm C}_1\text{-}{\rm C}_5$ alkyl; and

n is 0 to 2, and the pharmaceutically acceptable salts, esters, and amides thereof, wherein the esters thereof are selected from C_1 - C_6 alkyl esters, C_5 - C_7 cycloalkyl esters, and arylalkyl esters and the amides thereof are derived from ammonia, primary C_1 - C_6 alkyl amines, secondary C_1 - C_6 dialkyl, and 5- and 6-membered heterocyclic amines containing one nitrogen atom; and wherein the group $S(=0)_2M$ is optionally bonded to the 1-, 2-, or 3-position of Formula I.

5